此外，宜明昂科近日公告，IMM0306治疗系统性红斑狼疮(SLE)的Ib期临床试验成功完成首例患者给药。由集团独立研发的IMM0306是一种靶向分化簇47(CD47)及分化簇20(CD20)的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，集团拥有IMM0306的全球知识产权及商业化权利。Yiming Angke-B (01541) rose more than 21% in the morning session, as of the time of publication, up 19.09% to 8.69 Hong Kong dollars, with a turnover of 74.3424 million Hong Kong dollars.
According to the Wise Financial APP, Yiming Angke-B (01541) rose more than 21% in the morning session, as of the time of publication, up 19.09% to 8.69 Hong Kong dollars, with a turnover of 74.3424 million Hong Kong dollars.
On the news front, Yiming Angke announced that on October 25, 2024, the company has submitted a filing to the China Securities Regulatory Commission for the planned implementation of H股全流通, to convert a total of 14.114 million shares of the company's unlisted shares into H股. As of the date of this announcement, the company has not completed the filing procedures with the China Securities Regulatory Commission, and the details of the implementation plan for conversion and listing are yet to be finalized.
In addition, Yiming Angke recently announced the successful completion of the first patient dosing in the Ib phase clinical trial of the IMM0306 treatment system for systemic lupus erythematosus (SLE). The IMM0306 independently developed by the group is a bispecific molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), the world's first CD47 and CD20 bispecific molecule to enter clinical stage. As of the date of this announcement, the group holds the global intellectual property and commercialization rights to IMM0306.
